Open AccessNeutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
Author(s) -
Olivier Bylicki,
D. Delarbre,
Aurélie Mayet,
Audrey Ferrier,
Anne Périsse,
Carine Malle,
Jacques Cobola,
Antoine Bronstein,
Nastasia Menoud,
Elodie Valero-Biance,
Olivier Ferraris,
Frédéric Janvier,
JeanNicolas Tournier
Publication year - 2021
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2021.09.002
Subject(s) - asymptomatic , medicine , serology , seroconversion , context (archaeology) , vaccination , population , immunology , cohort , antibody , biology , paleontology , environmental health
A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the vaccination strategy. This study assessed the persistence of neutralizing antibody (Nab) activity and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients 9 months post symptom onset (PSO) in a primary care context among immunocompetent adults.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom